查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1836847

医药契约製造市场按服务类型、分子类型、剂型、客户类型、治疗领域、合约类型、製造规模和製程类型划分 - 全球预测，2025-2032 年

Pharmaceutical Contract Manufacturing Market by Service Type, Molecule Type, Dosage Form, Customer Type, Therapeutic Area, Contract Type, Production Scale, Process Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，医药契约製造市场规模将成长至 2,411.6 亿美元，复合年增长率为 8.70%。

主要市场统计数据
基准年2024年 1236.4亿美元
预计2025年 1344.4亿美元
预测年份：2032年 2411.6亿美元
复合年增长率（%） 8.70%

关于契约製造如何从成本主导的选择转变为医药创新和供应弹性的战略能力的权威定位

医药受託製造领域在全球医药供应链中发挥着至关重要的作用，使创新者、学名药製造商和生物相似药开发商能够将实验室突破转化为可扩展且受监管的商业产品。外包製造、配方开发、分析测试和包装已从一种成本控制策略发展成为一种战略能力，有助于加快产品上市速度、提高产品组合灵活性并分散风险。如今，价值链上的相关人员不再将受託製造厂商(CMO) 视为单纯的产能供应商，而是将共用技术风险、合规管道和生命週期管理责任的合作伙伴。

当今的格局受到多重压力的影响：复杂的生技药品形式需要专业的无菌和低温运输能力；监管部门对稳健的品质系统和供应可追溯性的期望；以及商业领域对更快的临床到商业化转型的需求。在这些动态中，整合开发专业知识、分析深度和商业规模生产的一体化服务模式正变得越来越重要。因此，具有前瞻性的申办者优先考虑长期技术合作关係、模组化生产布局和供应风险透明度，并将受託製造定位为其药物创新和分销策略的核心节点。

技术进步、监管加强和地缘政治压力如何共同重新定义製造外包能力和战略采购模式

在技​​术进步、监管日益复杂以及相关人员不断变化的期望的推动下，近期趋势正在迅速改变支持药物开发和商业化的受託製造格局。先进生技药品、细胞和基因疗法的兴起正推动合约製造生产组织 (CDMO) 投资无菌注射和低温运输平台，而持续生产和工艺集约化正在重新定义製造经济学和设施设计。这些转变并非孤立存在；它们同时再形成了整个产业的商业性采购模式、资本规划和人才需求。

全球监管机构对设计品质、流程稳健性和供应链透明度的要求日益提高，这促使製造商及其合作伙伴在整个开发和製造生命週期中嵌入分析和数位线程功能。同时，该行业的地理布局正在适应地缘政治和贸易趋势，本地製造能力、双重采购策略和近岸外包正在成为缓解干扰的机制。总而言之，这些变革力量有利于那些能够展示平台标准化、跨模式专业知识以及将监管、技术和商业需求整合到一致交付模式中的敏捷方法的契约製造製造商。

了解 2025 年美国新关税的广泛营运和商业影响，以及它们将如何重塑采购、投资和承包策略

美国将于2025年生效的关税措施调整，将给药品成分、包装组件、资本设备等采购计算带来新的复杂性，迫使契约製造製造商及其赞助商客户重新评估其成本结构和供应风险模型。某些进口材料和设备的关税上调，推高了无菌填充、专用包装基材、先进分析设备等关键零件的到岸成本。临床供应预算面临压力，新设施和设备的资本支出计画需要重新调整，赞助商和CDMO之间的定价谈判必须考虑到不断上升的投入成本波动。

除了直接的成本影响外，关税还在加速改变长期产业结构的策略行动。一些发起人正在优先考虑重新共享和近似共享倡议，以减少贸易摩擦的影响，从而增加了对无菌药品、生技药品灌装和特种包装国内生产能力的需求。拥有灵活生产模式和多个地理位置的契约製造製造商正受到寻求快速紧急应变方案和更短物流链的客户日益增长的兴趣。同时，受关税影响地区的原料供应商正在探索重新认证途径、双重采购安排和关税工程解决方案，以保持竞争力。

这些政策变化的累积效应也反映在供应商谈判和商业合约中。成本升级条款、转嫁机制和库存融资安排正成为新契约的重点。申办者和CDMO正在寻求提高材料成分和来源的透明度，并越来越同意长期采购承诺以确保价格稳定。此外，监管机构和行业协会正在进行对话，以维持基本药品的供应连续性，促使相关人员制定了应急方案，将战略库存、多个製造地和关键成分的优先分配框架结合起来。

简言之，2025年的关税并非暂时的价格衝击，而是结构性变革的催化剂。关税促使筹资策略转向弹性和在地化，提升了製造弹性的价值，并迫使商业环境与供应链现实更加协调一致。积极将关税风险纳入情境规划、资本投资决策和供应商管治的企业，将更有能力维持供应连续性，并保障净利率，同时确保合规性和产品品质。

策略性細項分析揭示了服务、分子、剂型、客户原型、治疗重点细分、合约模式、製造规模和製程选项等方面的产能需求

细緻的细分视角揭示了服务模式、分子类别、剂型、客户原型、治疗重点、合约模式、製造阶段和製程设计方案等方面的能力差距和策略重点。服务类型的专业化涵盖：涵盖生物分析操作、分析方法开发和稳定性测试的分析服务；涵盖配方和製程开发的开发服务；包括注射器、单位剂量和管瓶灌装的灌装服务；面向液体口服剂型、固体口服剂型、无菌注射剂和外用剂型的製造服务；以及满足一级和二级包装需求的包装和标籤服务。每种服务所需的资本强度、监管管道和技术能力各不相同，能够提供开发、分析表征和商业化生产之间整合交接的公司将为申办者创造上市时间优势。

分子类型决定了技术复杂性和设备要求。生技药品需要专门的上游和下游製程、低温运输考量和无菌处理方案，而小分子通常适用于成熟的口服口服固体製剂和液体生产平台。液体製剂（包括口服溶液和混悬液）需要辅料采购和稳定性方面的专业知识；固态胶囊和片剂需要强大的配方开发和压片灌装能力；无菌注射剂需要严格的无菌操作和检验的灌装设备；局部製剂（例如乳膏、软膏和凝胶）需要配方流变性控制和容器相容性测试。

客户类型和治疗领域决定了商业性参与模式。生物相似药製造商通常寻求大量商业化生产能力和法规可比性方面的专业知识，学名药药製造商优先考虑快速扩大规模和经济高效的工具，而创新药製造商则要求整合的开发管道和管理技术转移。心血管、中枢神经系统、感染疾病和肿瘤等治疗领域有不同的要求，包括临床供应链时间安排、包装和标籤的复杂性以及监管互动。产品类型和生产规模引入了管治和利用动态。专用合约提供保证的生产能力和长期协调，而非专用模式则提供了灵活性，但需要更复杂的调度。临床规模生产对I、II和III期试验有独特的需求，需要快速的技术转移和批次文件实践，这与商业规模的营运有很大不同。最后，流程类型（批量或连续）会影响资本部署、流程监控的复杂性和扩大规模的影响。连续製程可以为某些模式实现更高的吞吐量和更稳定的产品质量，但需要更先进的製程控制和即时分析能力。将能力与这些细分轴进行映射，可以让相关人员确定在哪里加强伙伴关係、在哪里投资能力发展以及在哪里优先降低风险以支持治疗和商业目标。

美洲、欧洲、中东和非洲以及亚太地区的製造能力、监管复杂性和策略奖励如何影响製造足迹和采购决策

区域动态正在影响製造能力的建设地点、供应风险的管理方式以及哪些监管机构主导商业性考量。在美洲，对无菌注射剂、填充封口先进生技药品以及安全供应链的需求正在推动国内製造能力的投资和专业化。该地区监管清晰、商业市场庞大且靠近主要申办方总部，这些优势使其对近岸外包计划以及寻求更短前置作业时间和更快速技术合作的申办方具有吸引力。

欧洲、中东和非洲的监管格局和能力各异，成熟的CDMO和利基创新企业并存。欧洲製造网路通常强调统一的监管途径和先进的工艺技术，而该地区其他国家则提供差异化的成本结构和新兴的专业能力。区域内跨境监管的一致性会影响多国的批次放行策略以及集中品质监控的实施地点，进而影响多站点製造网路的设计。

亚太地区继续成为重要的製造能力中心，为小分子药物、学名药生技药品和无菌製剂提供广泛的製造地。该地区凭藉其成本竞争力、深厚的辅料和包装材料供应商网路以及不断壮大的技术人才库，成为临床和商业生产的中心。同时，亚太地区多个市场日益完善的法规和不断增长的国内需求，正推动当地供应商升级品质系统并寻求国际认证。

在这些全部区域，供应链韧性、监管趋同以及对本地製造的策略奖励是影响投资决策的通用主题。申办方和製造外包製造商在配置其全球布局时，必须权衡成本、前置作业时间、监管复杂性和风险敞口。

探索能力整合、平台专业化和深度客户伙伴关係如何改变合约製造公司的竞争定位

领先的合约製造和服务供应商的竞争动态体现在能力整合、平台差异化以及超越交易关係的深化客户伙伴关係关係。许多公司正在透过提供从开发到商业的一体化解决方案来提升价值链，以减少技术转移中的摩擦并加快商业化进程。这一趋势体现在扩展分析平台以支援复杂的生技药品、投资无菌填充能力，以及采用数位化品质和製造执行系统以实现更可预测的结果。

策略伙伴关係、合併以及有针对性的待开发区投资正被用于扩大医疗模式覆盖范围和地理布局，而中型专科参与企业往往透过专注于诸如高效价处理、复杂包装或快速临床供应等利基能力而取得成功。对于申办者而言，合作伙伴的选择反映了规模、技术专长和监管经验深度之间的平衡。采购团队越来越优先考虑那些能够证明可验证的流程稳健性、成功的技术转移记录以及对多供应商供应链进行透明管治的合作伙伴。

人才和领导的持续性是关键的差异化因素。拥有涵盖研发科学、法规事务、品质保证和卓越营运等跨职能团队的组织，更有能力推进复杂计划，并最大程度地减少产品发布延迟。此外，提供清晰的产能扩张蓝图和紧急应变计画的公司，往往能获得寻求降低产品发布和生命週期供应风险的客户所做出的长期承诺。

製造商和赞助商可以采取切实可行的策略行动，以提高灵活性、降低供应风险，并使商业性框架与不断发展的製造业现实保持一致

产业领导者应优先考虑一系列战术性和战略行动，将当前的市场动态转化为永续优势。首先，选择性地投资模组化、灵活的生产平台，这些平台可以容纳多种剂型和分子类别，从而实现计划之间的快速重新部署，并​​减少设备重组的时间。整合强大的分析技术和数位化流程控制，支持「品质源自于设计」的概念，并使从临床到商业化生产的规模化进程更加顺畅。

其次，重新评估您的供应商和筹资策略，以降低海关和物流风险。这可能包括多元化投入品供应商、协商更清晰的转嫁条款，以及在可行的情况下开发近岸替代方案。透明的原产地证明文件和积极主动的供应商资格审查方法将提升您的谈判能力，并减少下游意外情况。

第三，透过将製剂、分析和製程开发团队与生产团队并置或紧密整合，加强一体化开发管道。这种合作可以缩短反馈循环，加速技术转移，并减少规模化生产过程中的监管摩擦。此外，还要製定正式的应急方案，以应对关键材料短缺或监管延迟，包括优先分配标准以及与值得信赖的合作伙伴预先商定的突波能安排。

第四，与客户采用以结果为导向的商业模式，例如里程碑挂钩定价和风险分担安排，以更好地协调奖励并应对投入成本波动。制定合约框架，其中包含明确的投入成本衝击升级机制，同时维持变革管理的协作管治。最后，优先发展人才发展项目，对科学家、品质专业人员和营运人员进行交叉培训，以增强组织韧性，并在关键过渡阶段减少对个人或团队的依赖。

采用严格的混合方法研究途径，结合主要相关人员访谈、文件检验和情境压力测试，以获得有弹性的策略见解

本分析所依据的研究将结构化的一手资料与行业相关人员、严谨的二手资料整合以及基于场景的供应链压力测试相结合，以确保获得切实可行的见解。主要工作包括与申办方和受託製造製造商的研发科学、品质保证、法规事务、采购和营运部门的高阶领导进行访谈。这些对话重点在于能力差距、近期投资、技术转移经验以及对政策和供应中断的实际应对措施。

二次研究考察了监管指南文件、技术白皮书和公开的企业资料，以检验观察到的趋势并绘製能力足迹图。在可能的情况下，我们还进行了生产基地描述、设施审核和交叉引用的备案历史记录，以支援关于服务交付和模式覆盖范围的断言。情境分析模拟了供应中断、关税引发的成本衝击以及生产能力损失事件，以评估各种采购配置和合约结构的弹性。

分析方法包括跨细分维度的能力映射、定性比较分析（用于识别高绩效供应商之间的差异化实践）以及在各种颠覆情境下对采购和承包槓桿进行敏感性测试。研究过程强调三角测量，力求在访谈资料、文献证据和情境结果之间达成一致，以得出确凿的结论，同时承认政策轨迹和资本部署时间表存在不确定性。

简要总结产能整合、供应多样化和现代承包如何成为合约製造竞争韧性的支柱。

受技术、监管、商业性和地缘政治因素的影响，製药製造合约和营运的格局正在迅速演变。投资于平台多功能性、高级分析和数位化控制的契约製造製造商最有能力满足生技药品和小分子产品赞助商的复杂需求。策略性采购选择，包括近岸外包和供应商多元化，已成为管理成本和连续性风险的重要槓桿，尤其是在不断变化的贸易政策可能对投入经济产生重大影响的环境下。

能够整合开发、分析和商业製造功能，最大限度地减少技术转移摩擦并加快进度的组织将获得长期竞争优势。同时，强而有力的供应商来源管治和透明分配投入成本风险的合约机制，对于保护净利率和维持可靠供应至关重要。未来将青睐以合作为伙伴关係的模式，这些模式能够协调奖励，并共用产品品质和及时市场进入的课责。果断采取行动，加强灵活产能、制定应急计画并现代化合约方式的决策者，将能够将当前的混乱转化为持久的策略效益。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 对提供全整合生物製药开发和製造服务的 CDMO 的需求不断增加
  • 越来越多地采用连续製造技术来提高製程效率和质量
  • 采用永续绿色化学实践的小分子 API契约製造越来越受到青睐
  • 个人化医疗的发展需要针对细胞和基因治疗的灵活契约製造解决方案
  • 製药公司与 CDMO 建立策略伙伴关係关係，推动端到端流程数位化和自动化
  • 在整个外包製造工作流程中实施先进的品质分析和即时过程监控
  • 主要市场的监管协调正在推动对拥有全面全球合规专业知识的 CDMO 的需求
  • 疫苗和肿瘤供应链优先事项推动无菌注射契约製造需求激增
  • 增加对一次性反应器技术的投资，以加速生物製药契约製造规模化进程
  • 将人工智慧驱动的流程优化平台整合到製药契约製造营运中，以提高产量比率

第六章 2025年美国关税的累积影响

第七章 人工智慧的累积影响，2025年

8. 医药契约製造市场（依服务类型）

  • 分析服务
    • 生物分析服务
    • 方法开发
    • 稳定性研究
  • 开发服务
    • 配方开发
    • 製程开发
  • 灌装服务
    • 注射器填充
    • 单位剂量灌装
    • 管瓶灌装
  • 製造服务
    • 液体口服製剂
    • 口服固态製剂
    • 无菌注射剂
    • 外用药物
  • 包装和标籤
    • 初级包装
    • 二次包装

9. 按分子类型分類的医药契约製造市场

  • 生技药品
  • 小分子

第 10 章 药品契约製造市场（以剂型）

  • 液体剂量
    • 口服溶液
    • 暂停
  • 固态剂型
    • 胶囊
    • 药片
  • 无菌注射剂
  • 局部剂量
    • 乳膏和软膏
    • 凝胶

第 11 章：按客户类型分類的医药契约製造市场

  • 生物相似药製造商
  • 学名药製造商
  • 创新製造商

第 12 章：按治疗领域分類的医药契约製造市场

  • 心血管系统
  • 中枢神经系统
  • 感染疾病
  • 肿瘤学

第 13 章：按合约类型分類的医药契约製造市场

  • 专用型
  • 非专用

第十四章 医药契约製造市场（依製造规模）

  • 实验室检查
    • 第一阶段
    • 第二阶段
    • 第三阶段
  • 商业的

第 15 章：按製程类型分類的医药契约製造市场

  • 批次
  • 连续的

第 16 章：按地区分類的医药契约製造市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十七章 医药契约製造市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 18 章：各国医药契约製造市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十九章 竞争态势

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Lonza Group AG
    • Catalent, Inc.
    • Thermo Fisher Scientific Inc.
    • Samsung Biologics Co., Ltd.
    • Wuxi AppTec Co., Ltd.
    • Fujifilm Diosynth BIoTechnologies US, LLC
    • Recipharm AB
    • Siegfried Holding AG
    • Cambrex Corporation
    • PCI Pharma Services, Inc.
Product Code: MRR-030EE48515DD

The Pharmaceutical Contract Manufacturing Market is projected to grow by USD 241.16 billion at a CAGR of 8.70% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 123.64 billion
Estimated Year [2025] USD 134.44 billion
Forecast Year [2032] USD 241.16 billion
CAGR (%) 8.70%

An authoritative orientation to how contract manufacturing has transformed from a cost-driven option into a strategic capability for pharmaceutical innovation and supply resilience

The pharmaceutical contract manufacturing arena occupies a pivotal role in the global medicines supply chain, enabling innovators, generics players, and biosimilar developers to translate laboratory breakthroughs into scalable, regulated commercial products. Outsourcing of production, formulation development, analytical testing, and packaging has evolved from a cost containment tactic into a strategic capability that supports speed to market, portfolio flexibility, and risk diversification. Stakeholders across the value chain now view contract manufacturing organizations as partners that co-own technical risk, compliance pathways, and lifecycle management responsibilities rather than as mere capacity vendors.

Today's landscape is shaped by converging pressures: complex biologic modalities that require specialized sterile and cold-chain capabilities; regulatory expectations for robust quality systems and supply traceability; and commercial demands for faster clinical-to-commercial transitions. These dynamics have elevated the importance of integrated service models that combine development expertise, analytical depth, and commercial-scale manufacturing. Consequently, forward-looking sponsors prioritize long-term technical relationships, modular manufacturing footprints, and transparency in supply risk, positioning contract manufacturers as central nodes in pharmaceutical innovation and distribution strategies.

How technological advances, regulatory tightening, and geopolitical pressures are converging to redefine contract manufacturing capabilities and strategic sourcing models

Recent years have seen a rapid reshaping of how contract manufacturing supports drug development and commercialization, driven by technological advances, regulatory complexity, and evolving stakeholder expectations. The rise of advanced biologics and cell and gene therapies has pushed CDMOs to invest in sterile injectables and cold chain platforms, while continuous manufacturing and process intensification have begun to reframe production economics and facility design. These shifts are not isolated; they simultaneously reshape commercial sourcing models, capital planning, and talent requirements across the industry.

Regulators globally are reinforcing expectations for quality-by-design, process robustness, and supply chain transparency, prompting manufacturers and their partners to embed analytics and digital thread capabilities across development and production lifecycles. Meanwhile, the industry's geographic footprint is adapting to geopolitical and trade developments, with localized capacity, dual-sourcing strategies, and nearshoring gaining prominence as mechanisms to mitigate disruption. Taken together, these transformative currents favor contract manufacturers that can demonstrate platform standardization, cross-modal expertise, and an agile approach to integrating regulatory, technical, and commercial needs into cohesive delivery models.

Understanding the broad operational and commercial consequences of new United States tariff measures in 2025 and how they reshape sourcing, investment, and contractual strategies

The tariff policy adjustments implemented by the United States in 2025 have introduced a new layer of complexity into the sourcing calculus for pharmaceutical ingredients, packaging components, and capital equipment, compelling both contract manufacturers and their sponsor customers to revisit cost structures and supply risk models. Increased duties on certain imported materials and equipment have translated into higher landed costs for components essential to sterile filling, specialized packaging substrates, and sophisticated analytical instrumentation. This dynamic has consequences across the development-to-commercial continuum: clinical supply budgets are pressured, capital expenditure plans for new facilities or equipment require recalibration, and pricing discussions between sponsors and CDMOs must account for elevated input cost volatility.

Beyond the direct cost impact, the tariffs have accelerated strategic behaviors that alter long-term industry structure. Some sponsors have prioritized re-shoring or near-shoring initiatives to reduce exposure to trade friction, which in turn increases demand for domestic capacity in steriles, biologics fill-finish, and specialized packaging. Contract manufacturers with flexible production models and multi-jurisdictional footprints have found increased interest from customers seeking rapid contingency options and shorter logistics chains. At the same time, suppliers of raw materials located in tariff-affected geographies are exploring re-certification pathways, dual-sourcing arrangements, and tariff-engineering solutions to preserve competitiveness.

The cumulative effect of these policy changes extends to supplier negotiations and commercial contracting. Cost escalation clauses, pass-through mechanisms, and inventory financing arrangements have become focal points of new contracts. Sponsors and CDMOs are seeking greater transparency on bill-of-materials composition and origin, and are more frequently agreeing to longer-term procurement commitments to secure stable pricing. Moreover, regulatory authorities and industry groups have engaged in dialogue about maintaining supply continuity for essential medicines, which has encouraged stakeholders to develop contingency playbooks that combine strategic stockpiles, multiple manufacturing sites, and prioritized allocation frameworks for critical components.

In sum, tariffs enacted in 2025 function less as a temporary price shock and more as a catalyst for structural change: they have shifted sourcing strategies toward resilience and localization, elevated the value of manufacturing flexibility, and forced sharper alignment between commercial terms and supply chain realities. Organizations that proactively integrate tariff risk into scenario planning, capital investment decisions, and supplier governance will be better positioned to sustain supply continuity and preserve margins while maintaining compliance and product quality.

Strategic segmentation analysis revealing capability demands across services, molecules, dosage forms, customer archetypes, therapeutic focuses, contract models, production scales, and process choices

A nuanced segmentation view reveals where capability gaps and strategic priorities converge across service modalities, molecule classes, dosage formats, customer archetypes, therapeutic focus, contract models, production phases, and process design choices. Service-type specialization spans analytical services that cover bioanalytical work, method development, and stability studies; development services that encompass formulation and process development; filling services that include syringe, unit dose, and vial filling; manufacturing services oriented to liquid orals, solid oral dosage, sterile injectables, and topical formulations; and packaging and labeling services that address primary and secondary packaging needs. Each service strand demands distinct capital intensity, regulatory pathways, and technical competencies, and firms that can offer integrated handoffs between development, analytical characterization, and commercial manufacturing create tangible time-to-market advantages for sponsors.

Molecule type drives technical complexity and facility requirements. Biologics require specialized upstream and downstream processing, cold chain considerations, and sterile handling regimes, while small molecules often align with established solid oral or liquid oral manufacturing platforms. Dosage form segmentation further refines capability needs: liquid dosage formats including oral solutions and suspensions necessitate excipient sourcing and stability expertise; solid dosage capsules and tablets demand robust formulation development and compression/fill capabilities; sterile injectables impose stringent aseptic practices and validated fill-finish suites; and topical dosage forms such as creams, ointments, and gels require formulation rheology control and container compatibility testing.

Customer type and therapeutic area shape commercial engagement models. Biosimilar manufacturers often seek high-volume commercial capacity and regulatory comparability expertise, generic manufacturers prioritize rapid scale-up and cost-efficient tooling, and innovator manufacturers demand integrated development pathways and controlled tech transfer. Therapeutic focus areas, such as cardiovascular, central nervous system, infectious diseases, and oncology, impose differing requirements for clinical supply chain timing, packaging and labeling complexity, and regulatory interaction intensity. Contract type and production scale introduce governance and utilization dynamics: dedicated contracts provide capacity assurance and long-term alignment, whereas non-dedicated models offer flexibility but require more complex scheduling. Clinical-scale production, with phase-specific needs across Phase I, II, and III, requires nimble tech transfer and batch documentation practices that differ materially from commercial-scale operations. Finally, process type-batch versus continuous-affects capital deployment, process monitoring complexity, and implications for scale-up. Continuous processes can enable higher throughput and more consistent product quality for certain modalities but require a higher level of process control and real-time analytical capabilities. Mapping capabilities against these segmentation axes allows stakeholders to identify where to consolidate partnerships, where to invest in capability development, and where to prioritize risk mitigation to support therapeutic and commercial objectives.

How regional capacity, regulatory complexity, and strategic incentives in the Americas, Europe Middle East & Africa, and Asia-Pacific shape manufacturing footprints and sourcing decisions

Regional dynamics are shaping where capacity is built, how supply risk is managed, and which regulatory touchpoints dominate commercial considerations. In the Americas, demand for sterile injectables, advanced biologics fill-finish, and secure supply chains has driven investments in domestic capacity and specialization. This region's combination of regulatory clarity, large commercial markets, and proximity to major sponsor headquarters makes it attractive for nearshoring initiatives and for sponsors seeking shorter lead times and more responsive technical collaboration.

Europe, Middle East & Africa represents a diverse regulatory and capability landscape where established CDMOs co-exist with niche innovators. European manufacturing networks often emphasize harmonized regulatory pathways and advanced process technologies, while countries across the broader region offer differentiated cost structures and emerging specialized capabilities. Cross-border regulatory alignment within this region influences where multicountry batch release strategies and centralized quality oversight are implemented, which affects the design of multi-site manufacturing networks.

Asia-Pacific continues to be a critical capacity hub, offering broad manufacturing bases for small molecules, generics, and an expanding footprint for biologics and sterile manufacturing. The region's competitive cost profile, deep supplier networks for excipients and packaging materials, and growing technical talent pool make it a central node for both clinical and commercial production. Simultaneously, increasing regulatory sophistication in several Asia-Pacific markets and rising domestic demand are pushing local providers to upgrade quality systems and to pursue international certifications, which in turn broadens the set of viable sourcing options for global sponsors.

Across these geographies, supply chain resilience, regulatory convergence efforts, and strategic incentives for local manufacturing are the common themes influencing investment decisions. Sponsors and contract manufacturers must evaluate trade-offs between cost, lead time, regulatory complexity, and risk exposure when configuring global footprints; the optimal approach increasingly blends regional centers of excellence with redundant capacity and rapid-response capabilities.

Insights into how capability consolidation, platform specialization, and deep client partnerships are reshaping competitive positioning among contract manufacturing providers

Competitive dynamics among leading contract manufacturers and service providers are characterized by capability consolidation, platform differentiation, and deeper client partnerships that extend beyond transactional engagements. Many firms are moving up the value chain by offering integrated development-to-commercial solutions that reduce tech transfer friction and accelerate commercialization timelines. This trend is visible in the expansion of analytical platforms that support complex biologics, investments in sterile fill-finish capacity, and the adoption of digital quality and manufacturing execution systems to enable more predictable outcomes.

Strategic partnerships, mergers, and targeted greenfield investments are being used to expand modality coverage and geographic presence, while mid-sized specialized players often succeed by focusing on niche capabilities such as high-potency handling, complex packaging, or rapid-turn clinical supply. For sponsors, the choice of partner reflects a balance between scale, technical specialization, and the depth of regulatory experience. Increasingly, procurement teams value partners who can demonstrate demonstrable process ruggedness, a track record of successful tech transfers, and transparent governance over multi-supplier supply chains.

Talent and leadership continuity are notable differentiators. Organizations that retain cross-functional teams covering development sciences, regulatory affairs, quality assurance, and operational excellence are better equipped to navigate complex projects and minimize time-to-release delays. Additionally, firms that provide clear roadmaps for capacity expansion and contingency management tend to attract longer-term commitments from customers seeking to de-risk their product launches and lifecycle supply.

Practical strategic actions for manufacturers and sponsors to enhance flexibility, mitigate supply risks, and align commercial frameworks with evolving production realities

Industry leaders should prioritize a series of tactical and strategic actions to convert current market dynamics into sustainable advantage. First, invest selectively in modular and flexible manufacturing platforms that can accommodate multiple dosage forms and molecule classes, thereby enabling rapid redeployment across projects and reducing time lost to retooling. Embedding robust analytical technologies and digital process controls will support quality-by-design approaches and facilitate smoother scale-up pathways from clinical to commercial production.

Second, re-evaluate supplier and sourcing strategies to mitigate tariff exposure and logistical risk. This includes diversifying input suppliers, negotiating clearer pass-through clauses, and developing nearshore alternatives where feasible. Transparent supply-of-origin documentation and a proactive approach to supplier qualification will improve negotiating leverage and reduce downstream surprises.

Third, strengthen integrated development pathways by co-locating or tightly coordinating formulation, analytical, and process development teams with manufacturing operations. This alignment shortens feedback loops, accelerates tech transfer, and reduces regulatory friction at the point of scale-up. Complementary to this, establish formal contingency playbooks for critical material shortages and regulatory delays, including prioritized allocation criteria and pre-agreed surge capacity arrangements with trusted partners.

Fourth, adopt outcome-oriented commercial models with customers, such as milestone-linked pricing and risk-sharing arrangements, to better align incentives and accommodate input cost volatility. Develop contract frameworks that include clear escalation mechanisms for input cost shocks while preserving collaborative governance for change management. Finally, prioritize talent development programs that cross-train scientists, quality professionals, and operations staff to build institutional resilience and reduce dependency on single individuals or teams during critical transfer phases.

A rigorous mixed-methods research approach combining primary stakeholder interviews, documentary validation, and scenario stress testing to produce resilient strategic insights

The research underpinning this analysis combined structured primary engagement with industry stakeholders, rigorous secondary source synthesis, and scenario-based supply chain stress testing to ensure actionable and defensible insights. Primary engagement included interviews with senior leaders across development sciences, quality assurance, regulatory affairs, procurement, and operations from a spectrum of sponsor and contract manufacturing organizations. These conversations focused on capability gaps, recent investments, tech transfer experiences, and practical responses to policy or supply disruptions.

Secondary research reviewed regulatory guidance documents, technical white papers, and publicly available corporate disclosures to validate observed trends and to map capability footprints. Where possible, cross-referencing of production platform descriptions, facility audits, and filing histories was used to corroborate claims about service offerings and modality coverage. Scenario-based analysis simulated supply interruptions, tariff-induced cost shocks, and capacity loss events to evaluate the resilience of different sourcing configurations and contract structures.

Analytical methods included capability mapping across the segmentation dimensions, qualitative comparative analysis to identify differentiating practices among high-performing providers, and sensitivity testing of procurement and contracting levers under varying disruption scenarios. The research process emphasized triangulation, seeking concurrence across interview data, documentary evidence, and scenario outcomes to build robust conclusions while acknowledging uncertainty in policy trajectories and capital deployment timelines.

A concise synthesis of how capability integration, supply diversification, and modern contracting form the pillars of competitive resilience in contract manufacturing

The contractual and operational contours of pharmaceutical manufacturing are evolving rapidly under the influence of technological, regulatory, commercial, and geopolitical forces. Contract manufacturers that invest in platform versatility, advanced analytics, and digital controls will be best positioned to serve the complex needs of biologic and small-molecule sponsors alike. Strategic sourcing choices, inclusive of nearshoring and supplier diversification, have become critical levers to manage both cost and continuity risk, particularly in an environment where trade policy shifts can materially affect input economics.

Longer-term competitive advantage will accrue to organizations that can integrate development, analytical, and commercial manufacturing functions to minimize tech transfer friction and compress timelines. At the same time, strong governance over supplier origin and contractual mechanisms that transparently allocate input cost risk will be essential for preserving margins and maintaining reliable supply. The future will favor collaborative, partnership-oriented models that align incentives and create shared accountability for product quality and timely market access. Decision-makers who act decisively to fortify flexible capacity, codify contingency plans, and modernize contracting approaches will convert current disruption into durable strategic benefits.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing demand for CDMOs providing fully integrated biologics development and manufacturing services
  • 5.2. Rising adoption of continuous manufacturing technologies to enhance process efficiency and quality
  • 5.3. Growing preference for small molecule API contract manufacturing adopting sustainable green chemistry practices
  • 5.4. Expansion of personalized medicine requiring flexible contract manufacturing solutions for cell and gene therapies
  • 5.5. Strategic partnerships between pharmaceutical firms and CDMOs to drive end-to-end process digitalization and automation
  • 5.6. Implementation of advanced quality analytics and real-time process monitoring across outsourced production workflows
  • 5.7. Regulatory harmonization across major markets increasing demand for CDMOs with comprehensive global compliance expertise
  • 5.8. Surge in requests for sterile injectable contract manufacturing driven by vaccine and oncology supply chain priorities
  • 5.9. Increased investment in single-use bioreactor technologies to accelerate biologics contract manufacturing scale-up timelines
  • 5.10. Integration of AI-driven process optimization platforms into pharmaceutical contract manufacturing operations for yield improvement

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pharmaceutical Contract Manufacturing Market, by Service Type

  • 8.1. Analytical Services
    • 8.1.1. Bioanalytical Services
    • 8.1.2. Method Development
    • 8.1.3. Stability Studies
  • 8.2. Development Services
    • 8.2.1. Formulation Development
    • 8.2.2. Process Development
  • 8.3. Filling Services
    • 8.3.1. Syringe Filling
    • 8.3.2. Unit Dose Filling
    • 8.3.3. Vial Filling
  • 8.4. Manufacturing Services
    • 8.4.1. Liquid Orals
    • 8.4.2. Solid Oral Dosage
    • 8.4.3. Sterile Injectables
    • 8.4.4. Topical Formulations
  • 8.5. Packaging & Labeling
    • 8.5.1. Primary Packaging
    • 8.5.2. Secondary Packaging

9. Pharmaceutical Contract Manufacturing Market, by Molecule Type

  • 9.1. Biologics
  • 9.2. Small Molecule

10. Pharmaceutical Contract Manufacturing Market, by Dosage Form

  • 10.1. Liquid Dosage
    • 10.1.1. Oral Solutions
    • 10.1.2. Suspensions
  • 10.2. Solid Dosage
    • 10.2.1. Capsules
    • 10.2.2. Tablets
  • 10.3. Sterile Injectables
  • 10.4. Topical Dosage
    • 10.4.1. Creams & Ointments
    • 10.4.2. Gels

11. Pharmaceutical Contract Manufacturing Market, by Customer Type

  • 11.1. Biosimilar Manufacturers
  • 11.2. Generic Manufacturers
  • 11.3. Innovator Manufacturers

12. Pharmaceutical Contract Manufacturing Market, by Therapeutic Area

  • 12.1. Cardiovascular
  • 12.2. CNS
  • 12.3. Infectious Diseases
  • 12.4. Oncology

13. Pharmaceutical Contract Manufacturing Market, by Contract Type

  • 13.1. Dedicated
  • 13.2. Non Dedicated

14. Pharmaceutical Contract Manufacturing Market, by Production Scale

  • 14.1. Clinical Trial
    • 14.1.1. Phase I
    • 14.1.2. Phase II
    • 14.1.3. Phase III
  • 14.2. Commercial

15. Pharmaceutical Contract Manufacturing Market, by Process Type

  • 15.1. Batch
  • 15.2. Continuous

16. Pharmaceutical Contract Manufacturing Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Pharmaceutical Contract Manufacturing Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Pharmaceutical Contract Manufacturing Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2024
  • 19.2. FPNV Positioning Matrix, 2024
  • 19.3. Competitive Analysis
    • 19.3.1. Lonza Group AG
    • 19.3.2. Catalent, Inc.
    • 19.3.3. Thermo Fisher Scientific Inc.
    • 19.3.4. Samsung Biologics Co., Ltd.
    • 19.3.5. Wuxi AppTec Co., Ltd.
    • 19.3.6. Fujifilm Diosynth Biotechnologies US, LLC
    • 19.3.7. Recipharm AB
    • 19.3.8. Siegfried Holding AG
    • 19.3.9. Cambrex Corporation
    • 19.3.10. PCI Pharma Services, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AMERICAS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GCC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. G7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NATO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 36. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOANALYTICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOANALYTICAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOANALYTICAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOANALYTICAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOANALYTICAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOANALYTICAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY METHOD DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY METHOD DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY METHOD DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY METHOD DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY METHOD DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY METHOD DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STABILITY STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STABILITY STUDIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STABILITY STUDIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STABILITY STUDIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STABILITY STUDIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STABILITY STUDIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SYRINGE FILLING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SYRINGE FILLING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SYRINGE FILLING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SYRINGE FILLING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SYRINGE FILLING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SYRINGE FILLING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY UNIT DOSE FILLING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY UNIT DOSE FILLING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY UNIT DOSE FILLING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY UNIT DOSE FILLING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY UNIT DOSE FILLING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY UNIT DOSE FILLING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY VIAL FILLING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY VIAL FILLING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY VIAL FILLING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY VIAL FILLING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY VIAL FILLING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY VIAL FILLING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID ORALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID ORALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID ORALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID ORALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID ORALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID ORALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID ORAL DOSAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID ORAL DOSAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID ORAL DOSAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID ORAL DOSAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID ORAL DOSAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID ORAL DOSAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRIMARY PACKAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRIMARY PACKAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRIMARY PACKAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRIMARY PACKAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRIMARY PACKAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRIMARY PACKAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ORAL SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ORAL SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ORAL SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ORAL SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY STERILE INJECTABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CREAMS & OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CREAMS & OINTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CREAMS & OINTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CREAMS & OINTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CREAMS & OINTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CREAMS & OINTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CUSTOMER TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR MANUFACTURERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR MANUFACTURERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR MANUFACTURERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR MANUFACTURERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR MANUFACTURERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR MANUFACTURERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GENERIC MANUFACTURERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GENERIC MANUFACTURERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GENERIC MANUFACTURERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GENERIC MANUFACTURERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GENERIC MANUFACTURERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GENERIC MANUFACTURERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INNOVATOR MANUFACTURERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INNOVATOR MANUFACTURERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INNOVATOR MANUFACTURERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INNOVATOR MANUFACTURERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INNOVATOR MANUFACTURERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INNOVATOR MANUFACTURERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CNS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CNS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CNS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CNS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CNS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CNS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY NON DEDICATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY NON DEDICATED, BY REGION, 2025